Beneficial Effect of a Selective Adenosine A2A Receptor Antagonist in the APPswe/PS1dE9 Mouse Model of Alzheimer’s Disease

Abstract : Consumption of caffeine, a non-selective adenosine A2A receptor (A2AR) antagonist, reduces the risk of developing Alzheimer's disease (AD) and mitigates both amyloid and Tau lesions in transgenic mouse models of the disease. While short-term treatment with A2AR antagonists have been shown to alleviate cognitive deficits in mouse models of amyloidogenesis, impact of a chronic and long-term treatment on the development of amyloid burden, associated neuroinflammation and memory deficits has never been assessed. In the present study, we have evaluated the effect of a 6-month treatment of APPsw/PS1dE9 mice with the potent and selective A2AR antagonist MSX-3 from 3 to 9-10 months of age. At completion of the treatment, we found that the MSX-3 treatment prevented the development of memory deficits in APP/PS1dE9 mice, without significantly altering hippocampal and cortical gene expressions. Interestingly, MSX-3 treatment led to a significant decrease of Aβ1-42 levels in the cortex of APP/PS1dE9 animals, while Aβ1-40 increased, thereby strongly affecting the Aβ1-42/Aβ1-40 ratio. Together, these data support the idea that A2AR blockade is of therapeutic value for AD.
Type de document :
Article dans une revue
Frontiers in Molecular Neuroscience, Frontiers Media, 2018, 11, pp.235. 〈10.3389/fnmol.2018.00235〉
Liste complète des métadonnées

Littérature citée [2 références]  Voir  Masquer  Télécharger

https://www.hal.inserm.fr/inserm-01930489
Contributeur : David Blum <>
Soumis le : jeudi 22 novembre 2018 - 09:18:43
Dernière modification le : vendredi 23 novembre 2018 - 13:13:38

Fichier

fnmol-11-00235.pdf
Fichiers éditeurs autorisés sur une archive ouverte

Identifiants

Collections

Citation

Emilie Faivre, Joana Coelho, Katja Zornbach, Enas Malik, Younis Baqi, et al.. Beneficial Effect of a Selective Adenosine A2A Receptor Antagonist in the APPswe/PS1dE9 Mouse Model of Alzheimer’s Disease. Frontiers in Molecular Neuroscience, Frontiers Media, 2018, 11, pp.235. 〈10.3389/fnmol.2018.00235〉. 〈inserm-01930489〉

Partager

Métriques

Consultations de la notice

35

Téléchargements de fichiers

4